Lutathera Approval Positions Novartis To Regain NET Share Taken By Ipsen
The US FDA has approved Advanced Accelerator Applications' radiopharmaceutical Lutathera to treat GEP-NETs second time around, just four days after Novartis closed its acquisition of AAA. The product should help the Swiss firm regain ground its Sandostatin product has lost to Ipsen's Somatuline.
You may also be interested in...
Novartis' New Oncology CEO Liz Barrett Charts A Course, But It Will Require Jump-Starting New Brands
Liz Barrett joined Novartis in February after leading Pfizer's oncology unit, taking over leadership of the business at a time of transition and tasked with building new blockbusters as old reliable work engines mature. She talked to Scrip about her plans for Novartis Oncology at ASCO.
The Swiss major has divested a non-core asset at a decent price and its eye care unit Alcon could be next under the hammer as CEO Vas Narasimhan looks at bolt-on acquisitions to create "the leading medicines company, powered by digital and data."
The latest drug development news and highlights from our US FDA Performance Tracker.